[Retracted] Expression of Serum Omentin, CTRP9, and Vaspin in Patients with Polycystic Ovary Syndrome

Table 1

Comparison of clinical data and metabolism-related indexes of the four groups ( ±s).

Groups	n	Age (year)	BMI (kg/m^2)	WHR	FINS (mIU/L)
Study group A (obesity)	50	34.63 ± 6.09	27.84 ± 3.87^a	0.97 ± 0.07^a	24.93 ± 16.37^ac
Study group B (nonobesity)	50	33.81 ± 7.11	20.69 ± 1.62	0.84 ± 0.08	10.63 ± 6.92^d
Control group A (obesity)	50	35.25 ± 7.48	27.33 ± 4.25^b	0.96 ± 0.06^b	10.60 ± 6.84^b
Control group B (nonobesity)	50	34.66 ± 7.50	19.81 ± 1.60	0.82 ± 0.05	4.22 ± 1.91
F		1.326	63.269	13.731	35.536
		0.294	≤0.001	≤0.001	≤0.001
Groups	n	TG (mmol/L)	TC (mmol/L)	HDL-c (mmol/L)	LDL-c (mmol/L)
Study group A (obesity)	50	2.84 ± 0.89	4.67 ± 1.13	1.11 ± 0.24^a	3.32 ± 0.61
Study group B (nonobesity)	50	1.57 ± 1.08	4.62 ± 1.24	1.19 ± 0.35	2.79 ± 0.55
Control group A (obesity)	50	2.23 ± 1.46	4.57 ± 0.96	1.13 ± 0.21^b	3.22 ± 0.78
Control group B (nonobesity)	50	1.58 ± 0.92	4.38 ± 0.73	1.24 ± 0.35	2.97 ± 0.92
F		2.132	0.656	3.679	1.673
		0.110	0.592	0.015	0.179
Groups	n	HOMA-IR	TT (mmol/L)	Omentin (pg/L)	CTRP9 (ng/L)	Vaspin (μg/L)
Study group A (obesity)	50	6.37 ± 1.52^ac	1.47 ± 0.62^c	42.87 ± 19.52^a	239.31 ± 36.17^c	0.63 ± 0.44^ac
Study group B (nonobesity)	50	2.31 ± 1.57^d	1.41 ± 0.53^d	111.23 ± 34.74	241.76 ± 42.73^d	0.45 ± 0.34^d
Control group A (obesity)	50	2.26 ± 1.55^b	1.04 ± 0.87^b	45.91 ± 18.54^b	463.58 ± 64.72	0.33 ± 0.31^b
Control group B (nonobesity)	50	0.91 ± 0.38	0.93 ± 0.47	115.28 ± 33.78	461.39 ± 55.45	0.13 ± 0.10
F		22.341	4.131	60.308	206.516	6.782
		≤0.001	≤0.001	≤0.001	≤0.001	≤0.001